Podcasts about early detection

Is your body screaming for help? Would you know if you're ignoring life-threatening symptoms? Well, my guest today, Marisa Peters, is a passionate advocate for cancer awareness. She shares how the hustle and bustle of life can mask serious health signs, and why it's critical to listen to our bodies.  Marisa moved from a high-powered career as a Chief People Officer in the tech and entertainment industries to a late-stage rectal cancer diagnosis at 39. Marisa is now on a mission to raise awareness about colorectal cancer and empower others to take their health seriously. She's using her experience to educate and inspire, starting conversations that have been long overdue. If you're brushing off symptoms, thinking they're just part of life, this episode will inspire you to advocate for yourself and take action. You'll learn how to recognize the symptoms of colorectal cancer, why early screening is vital, and how one simple conversation can save lives.  "Be seen, get screened, use your voice, and be your biggest advocate 'cause you know your body best.. " ~ Marisa Peters In This Episode: - Meet Marisa Peters - Marisa's journey from a corporate career to cancer survivor - The diagnosis and how it changed everything - Her shift in perspective after receiving the cancer diagnosis  - Fighting for normalcy while battling cancer - Marisa's lessons on time, family, and self-care  - The importance of being seen and speaking up about health - When should healthy people get colorectal cancer screening? - How to get involved and help spread the word About Marisa Peters: Marisa Peters is a producer, speaker, and author -- living today as a young-onset rectal cancer survivor. As a former Broadway vocalist and national anthem singer for major league sports, Marisa pivoted to the corporate stage, serving as a Chief People Officer inside entertainment and tech companies.  Host of the podcast, From Carpools To Chemo, Marisa is using her voice in a new way by advocating for people to “Be Seen.” Her family launched the BE SEEN Foundation, which is on a mission to eradicate death by young-onset colorectal cancer after her successful treatment at UCLA Health.  Instagram: https://www.instagram.com/beseen.care/                    https://www.instagram.com/fromcarpoolstochemo/  Facebook: https://www.facebook.com/BeSeenBuzz  Website: www.beseen.care  Podcast: www.beseen.care/podcast            Where to find me: IG: https://www.instagram.com/jen_gottlieb/    TikTok: https://www.tiktok.com/@jen_gottlieb     Facebook: https://www.facebook.com/Jenleahgottlieb    Website: https://jengottlieb.com/    My business: https://www.superconnectormedia.com/     YouTube: https://www.youtube.com/@jen_gottlieb

"Any time the patient hears the word 'cancer,' they shut down a little bit, right? They may not hear everything that the oncologist or urologist, or whoever is talking to them about their treatment options, is saying. The oncology nurse is a great person to sit down with the patient and go over the information with them at a level they can understand a little bit more. To go over all the treatment options presented by the physician, and again, make sure that we understand their goals of care," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer treatment considerations for nurses.  Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by November 21, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the treatment of prostate cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 387: Prostate Cancer Screening, Early Detection, and Disparities Episode 373: Biomarker Testing in Prostate Cancer Episode 324: Pharmacology 101: LHRH Antagonists and Agonists Episode 321: Pharmacology 101: CYP17 Inhibitors Episode 208: How to Have Fertility Preservation Conversations With Your Patients Episode 194: Sex Is a Component of Patient-Centered Care ONS Voice articles: Communication Models Help Nurses Confidently Address Sexual Concerns in Patients With Cancer Exercise Before ADT Treatment Reduces Rate of Side Effects Frank Conversations Enhance Sexual and Reproductive Health Support During Cancer Nurses Are Key to Patients Navigating Genitourinary Cancers Sexual Considerations for Patients With Cancer The Case of the Genomics-Guided Care for Prostate Cancer ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (Second Edition) Manual for Radiation Oncology Nursing Practice and Education (Fifth Edition) Clinical Journal of Oncology Nursing articles: Brachytherapy: Increased Use in Patients With Intermediate- and High-Risk Prostate Cancers Physical Activity: A Feasibility Study on Exercise in Men Newly Diagnosed With Prostate Cancer The Role of the Advanced Practice Provider in Bone Health Management for the Prostate Cancer Population Oncology Nursing Forum articles: An Exploratory Study of Cognitive Function and Central Adiposity in Men Receiving Androgen Deprivation Therapy for Prostate Cancer ONS Guidelines™ for Cancer Treatment–Related Hot Flashes in Women With Breast Cancer and Men With Prostate Cancer Other ONS resources: Biomarker Database (refine by prostate cancer) Biomarker Testing in Prostate Cancer: The Role of the Oncology Nurse Brachytherapy Huddle Card External Beam Radiation Huddle Card Hormone Therapy Huddle Card Luteinizing Hormone-Releasing Hormone Antagonist Huddle Card Sexuality Huddle Card American Cancer Society prostate cancer page National Comprehensive Cancer Network homepage To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "I think it's important to note that urologists are usually the ones that are doing the diagnosis of prostate cancer and really start that staging of prostate cancer. And the medical oncologists usually are not consulted until the patient is at a greater stage of prostate cancer. I find that it's important to state because a lot of our patients start with urologists, and by the time they've come to us, they're a lot further staged. But once a prostate cancer has been suspected, the patient needs to be staged for the extent of disease prior to that physician making any treatment recommendations. The staging includes doing a core biopsy of the prostate gland. During this core biopsy, they take multiple different cores at different areas throughout the prostate to really look to see what the cancer looks like." TS 1:46 "[For] the very low- and low-risk group, the most common [treatment] is active surveillance. ... Patients can be offered other options such as radiation therapy or surgery if they're not happy with active surveillance. ... The intermediate-risk group has favorable and unfavorable [status]. So, if they're a favorable, their Gleason score is usually a bit lower, things are not as advanced. These patients are offered active surveillance and then either radical prostatectomy with possible removal of lymph nodes or radiation—external beam or brachytherapy. If a patient has unfavorable intermediate risk, they are offered radical prostatectomy with removal of lymph nodes, external radiation therapy plus hormone therapy, or external radiation with brachytherapy. All three of these are offered to patients, although most frequently we see that our patients are taken in for radical prostatectomy. For the high- or very high-risk [group], patients are offered radiation therapy with hormone therapy, typically for one to three years. And then radical prostatectomy with removal of lymph nodes could also be offered for those patients." TS 7:55 "Radiation can play a role in any risk group depending on the patient's preference. ... The types of radiation that we use are external beam, brachytherapy, which is an internal therapy, and radiopharmaceuticals, [which are] more for advanced cancer, but we are seeing them used in prostate [cancer] as well. External beam radiation focuses on the tumor and any metastasis we may have with the tumor. It can be used in any risk [group] and for recurrence if radiation has not been done previously. If a patient has already been radiated to the pelvic area or to the prostate, radiation is usually not given again because we don't want to damage the patient any further. Brachytherapy is when we put radioactive pellets directly into the prostate. For early-stage prostate cancer, this can be given alone. And for patients who have a higher risk of the cancer growing outside the prostate, it can be given in combination with external beam radiation. It's important to note with brachytherapy, it cannot be used on patients who've had a transurethral resection of the prostate or any urinary problems. And if the patient has a large prostate, they may have to be on some hormone therapy prior to brachytherapy, just to shrink that prostate down a little bit to get the best effect. ... Radiopharmaceuticals treat the prostate-specific membrane antigen." TS 11:05 "The side effects of surgery are usually what deter the patient from wanting surgery. The first one is urinary incontinence. A lot of times, a patient has a lot of urinary incontinence after they have surgery. The other one is erectile dysfunction. A lot of patients may not want to have erectile dysfunction. Or, if having an erection is important to the patient, they may not want to have surgery to damage that. In this day and age, physicians have gotten a lot better at doing nerve-sparing surgeries. And so they really do try to do that so that the patient does not have any issues with erectile dysfunction after surgery. But [depending on] the extent of the cancer where it's growing around those nerves or there are other things going on, they may not be able to save those nerves." TS 15:26 "Luteinizing hormone-releasing hormone, or LHRH antagonists or analogs, lower the amount of testosterone made by the testicles. We're trying to stop those hormones from growing to prevent the cancer. ... When we lower the testosterone very quickly, there can be a lot more side effects. But if we lower it a little bit less, we can maybe help prevent some of them. The side effects are important. When I was writing this up, I was thinking, 'Okay, this is basically what women go through when they go through menopause.' We're decreasing the estrogen. We're now decreasing the testosterone. So, the patients can have reduced or absent sexual desire, they can have gynecomastia, hot flashes, osteopenia, anemia, decreased mental sharpness, loss of muscle mass, weight gain, and fatigue." TS 17:50 "What we all need to remember is that no patient is the same. They may not have the same goals for treatment as the physicians or the nurses want for the patient. We talked about surgery as the most common treatment modality that's presented to patients, but it's not necessarily the option that they want. It's really important for healthcare professionals to understand their biases before talking to the patients and the family. It's also important to remember that not all patients are in heterosexual relationships, so we need to explain recovery after treatment to meet the needs of our patients and their sexual relationships, which is sometimes hard for us. But remembering that—especially gay men—they may not have the same recovery period as a heterosexual male when it comes to sexual relationships. So, making sure that we have those frank conversations with our patients and really check our biases prior to going in and talking with them." TS 27:16

Dr. Rachel Gatlin entered neuroscience with curiosity and optimism. Then came chaos. She started her PhD at the University of Utah in March 2020—right as the world shut down. Her lab barely existed. Her advisor was on leave. Her project focused on isolation stress in mice, and then every human on earth became her control group. Rachel fought through supply shortages, grant freezes, and the brutal postdoc job market that treats scientists like disposable parts. When her first offer vanished under a hiring freeze, she doubled down, rewrote her plan, and won her own NIH training grant. Her story is about survival in the most literal sense—how to keep your brain intact when the system built to train you keeps collapsing.RELATED LINKS• Dr. Rachel Gatlin on LinkedIn• Dr. Gatlin's Paper Preprint• Dr. Eric Nestler on Wikipedia• News Coverage: Class of 2025 – PhD Students Redefine PrioritiesFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

EPISODE DESCRIPTIONBefore she was raising millions to preserve fertility for cancer patients, Tracy Weiss was filming reenactments in her apartment for the Maury Povich Show using her grandmother's china. Her origin story includes Jerry Springer, cervical cancer, and a full-body allergic reaction to bullshit. Now, she's Executive Director of The Chick Mission, where she weaponizes sarcasm, spreadsheets, and the rage of every woman who's ever been told “you're fine” while actively bleeding out in a one-stall office bathroom.We get into all of it. The diagnosis. The misdiagnosis. The second opinion that saved her life. Why fertility preservation is still a luxury item. Why half of oncologists still don't mention it. And what it takes to turn permission to be pissed into a platform that actually pays for women's futures.This episode is blunt, hilarious, and very Jewish. There's chopped liver, Carrie Bradshaw slander, and more than one “fuck you” to the status quo. You've been warned.RELATED LINKSThe Chick MissionTracy Weiss on LinkedInFertility Preservation Interview (Dr. Aimee Podcast)Tracy's Story in Authority MagazineNBC DFW FeatureStork'd Podcast EpisodeNuDetroit ProfileChick Mission 2024 Gala RecapFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Closing the Gap: Understanding Gender Disparities in Bladder Cancer Care, hosted by Martha K. Terris, MD, FACS, is a limited series spotlighting unique considerations for bladder cancer diagnosis and treatment among women. Dr Terris is department chair and a professor in the Department of Urology, the Witherington Distinguished Chair in Urology, and co-director of the Cancer Center at the Medical College of Georgia at Augusta University. In the final part of this 3-part series, Dr Terris discussed how the early diagnosis of bladder cancer presents a significant challenge, particularly in female patients, who are frequently diagnosed at a later stage of the disease and subsequently respond less favorably to treatment modalities. A crucial component of early detection is the rigorous evaluation of hematuria, she emphasized. Microhematuria is defined strictly by microscopy. Reliance solely on a dipstick test is insufficient; any positive dipstick result necessitates a microscopic examination, she explained. Furthermore, patients currently receiving anticoagulation therapy do not bypass the standard workup, she noted. If hematuria is identified alongside a urinary tract infection or gynecological issue, the urine should be rechecked once the co-existing problem has cleared, she advised. Risk assessment must consider both common and less-recognized factors, particularly in women, according to Terris. Standard risks include exposure to cyclophosphamide or ifosfamide, Lynch syndrome, chronic indwelling Foley catheters, benzene/aromatic amine exposure, and smoking, she added. However, uro-oncologists must actively assess female patients for occupational exposures not traditionally associated with bladder cancer, she said. Patients presenting with microhematuria should be stratified into low-, intermediate-, or high-risk groups, Terris continued. The gold standard evaluation for high-risk patients is a cystoscopy and CT urogram, she reported. The CT urogram involves cross-sectional imaging of the abdomen and pelvis with and without contrast, incorporating delayed images to optimally visualize the renal pelvis and ureters for potential filling defects, she noted. If patients cannot tolerate contrast, an MR urogram is the primary alternative, she stated. If neither CT nor MR urogram can be performed, the default workup is non-contrast CT combined with cystoscopy and retrograde pyelograms, although this requires general anesthesia, she explained. Given that women are often diagnosed with bladder cancer late and face poor outcomes with advanced disease, maintaining a heightened awareness and low threshold for investigation is critical, Terris concluded.

Send us a textWhole body MRI is changing prevention from a guess into something you can actually see. Dr. Kevin White talks with Dr. Dan Durand, Johns Hopkins trained radiologist and Chief Medical Officer at Prenuvo, about how full body scans are catching silent problems early: from fatty liver and visceral fat to aneurysms, early cancers, and brain changes linked to cognitive decline and dementia. They unpack how Prenuvo's model pairs deep imaging, multiomic data, and real conversations with clinicians so patients do not just get a data dump, but a clear plan for what to do next.“Think of a whole body MRI as a home inspection for your health: you want to find the hidden leaks before the ceiling caves in.” – Dr. Dan DurandYou'll hear: • Why traditional screening only looks at a few organs and what whole body MRI adds • How often Prenuvo finds serious issues early and what that means for real people • The link between visceral fat, brain volume, and long term cognitive health • How AI is being used to measure brain regions, muscle, and fat with precision • Why reassurance from a clean scan can be just as powerful as a life saving catch • How to think about timing, HSA dollars, and making this part of your prevention planLearn more about Prenuvo and their whole body MRI at prenuvo.com.

Veonet Ireland has announced the introduction of DR.NOON AI Software by HeartEye Diagnostics - an AI-powered retinal screening system capable of detecting early signs of cardiovascular and diabetic vascular risk from a single, non-invasive eye retinal scan. At a time of high waiting lists for ophthalmology and cardiology, at 53,000 and 45,000 patients respectfully, DR.NOON offers a powerful preventive tool that can identify risk before symptoms appear. Built on clinically validated deep learning algorithms, DR.NOON AI software analyses subtle vascular patterns in the retina to uncover early indications of systemic disease, including hypertension, atherosclerosis, and microvascular changes associated with diabetes. Retinal screening to detect eye disease It delivers instant, AI-driven reports that match the outperform traditional methods in five-year cardiovascular risk prediction. This will include actionable insights for patients, identifying key risk indicators with personalised recommendations for lifestyle modification and disease management. With World Diabetes Day approaching on 14 November, the timing could not be more relevant. Diabetes remains a leading cause of vision loss among working-age adults, yet early detection can prevent over 90% of diabetes-related blindness, as it enables faster referral, timely treatment, and improved long-term outcomes for patients. Regular visits to your optometrist and enrolling in the Diabetic Retinal Screening Programme are as important as attending your diabetic clinic appointments. This is due to the increased risk of glaucoma, cataract and diabetic eye disease as a result of a diabetes diagnosis. "Diabetes, heart disease and vision loss are deeply interconnected, yet often diagnosed too late," explains Dr. Farah Ibrahim, Consultant Ophthalmologist at Veonet Ireland. "DR.NOON AI software changes that landscape - predicting cardiovascular risk for patients through a simple eye scan. This is preventive care in action: faster insights, earlier intervention, and ultimately, fewer patients joining already overstretched waiting lists." To mark its Irish debut, DR.NOON will be showcased at Veonet Ireland's upcoming CPD-accredited event, The Future of Vision: Emerging Advancements in Diabetic Eye Disease, taking place in Cork this Thursday, 13 November. The session will bring together optometrists, nurses, pharmacists and ophthalmic technicians to explore developments in diabetes eye management & experience how AI-driven innovation can reshape multidisciplinary diabetic eye care. You can learn more about the event, and reserve your spot in person or online, here. About Veonet Ireland Part of Veonet, Europe's leading ophthalmology group, Veonet Ireland is dedicated to delivering world-class, affordable, and accessible specialist eye care across Ireland. Founded by renowned ophthalmologists who recognised the value of sharing expertise, networking, and best practices, Veonet continues to advance the quality of ophthalmic care for patients across Europe. Veonet Ireland provides a supportive and positive environment where specialists and staff can grow both personally and professionally. Being a clinically led organisation, it empowers ophthalmologists to shape services and procedures in line with the highest clinical standards. See more breaking stories here. More about Irish Tech News Irish Tech News are Ireland's No. 1 Online Tech Publication and often Ireland's No.1 Tech Podcast too. You can find hundreds of fantastic previous episodes and subscribe using whatever platform you like via our Anchor.fm page here: https://anchor.fm/irish-tech-news If you'd like to be featured in an upcoming Podcast email us at Simon@IrishTechNews.ie now to discuss. Irish Tech News have a range of services available to help promote your business. Why not drop us a line at Info@IrishTechNews.ie now to find out more about how we can help you reach our audience. You can also find and follow us on Twitter, Linke...

"It's critical to identify those mutations found that are driving the cancer's growth and guide the personalized treatment based on those results. And important to remember, too, early testing is crucial for patients with non-small cell lung cancer (NSCLC). In studies, it has been found to be associated with improved survival outcomes and reduced mortality," ONS member Vicki Doctor, MS, BSN, BSW, RN, OCN®, precision medicine director at the City of Hope Atlanta, GA, Chicago, IL, and Phoenix, AZ, locations, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the oncology nurse's role in NSCLC biomarker testing. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  This podcast is sponsored by Lilly Oncology and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications. Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 363: Lung Cancer Treatment Considerations for Nurses Episode 359: Lung Cancer Screening, Early Detection, and Disparities Episode 238: Cancer Genomics for Every Oncology Nurse Episode 157: Biomarker Testing Improves Outcomes for Patients With Non-Small Cell Lung Cancer ONS Voice articles: Non-Small Cell Lung Cancer Prevention, Screening, Diagnosis, Treatment, Side Effects, and Survivorship Only a Third of Patients With Advanced Cancer Get Biomarker Testing, Limiting Use of Potentially Effective Precision Therapies Precision Medicine in Lung Cancer: How Comprehensive Testing Optimizes Patient Outcomes Targeted Therapies Are Transforming the Treatment of Non-Small Cell Lung Cancer ONS book: Guide to Cancer Immunotherapy (second edition) ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing article: Using Nurse Navigators to Improve Timeliness of Biomarker Testing for Non-Small Cell Lung Cancer Oncology Nursing Forum article: Precision Medicine Testing and Disparities in Health Care for Individuals With Non-Small Cell Lung Cancer: A Narrative Review Other ONS resources: Best Practices for Biomarker Testing in Non-Small Cell Lung Cancer: A Case Study Genomics and Precision Oncology Learning Library Genomics Case Study: Precision Medicine in the Setting of Metastatic Non-Small Cell Lung Cancer Biomarker Database (refine by non-small cell lung cancer) Genomic Biomarkers Huddle Card Targeted Therapy Huddle Card National Comprehensive Cancer Network homepage To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "These biomarkers are used to provide information about cancer's characteristics or behavior. In oncology precision medicine specifically, molecular tests can help with diagnosing a cancer that is maybe an unknown primary. It can help with monitoring response to therapy, detect recurrence of disease before other tests can find that, predict prognosis or how aggressive the cancer may be, and guide treatment decisions for targeted therapies." TS 3:14 "Some of the key biomarkers recommended by the National Comprehensive Cancer Network (NCCN) to be tested in patients who have NSCLC are EGFR, ALK, KRAS, BRAF, MET exon 14 skipping mutation, HER2 which is a protein expression from an ErbB protein, PD-L1 which is a protein expression that's used to guide immunotherapy choices, and then finally there are three fusions: ROS1, RET, and NTRK. [These] are pretty rare but really important to be tested for in patients who have NSCLC." TS 3:46 "Another important challenge for nurses related to this topic is that these results may not reveal a targeted mutation for the patient and that could be very disappointing. So, being able to provide that emotional support to a patient if they have that result … you can actually reinforce with them that if [they] go onto another treatment that the physician decides to put [them] on, the tumor can change. New pathogenic variants can develop based on the treatment that they're getting, and another test can be done. And maybe at that time—a new biomarker that could be targeted—we'd be seeing on the new test." TS 7:32  "Another circumstance we didn't talk about yet is that maybe the result came back saying that the quality was not sufficient. And sometimes that happens, but that doesn't mean that we're at the end of the road, necessarily. So, you could explain to the patient that that may mean that possibly, a new biopsy would be ordered by the physician. Or if a new biopsy or another tissue sample is not available, then maybe the physician would pivot to sending a blood specimen for the molecular testing. So that would definitely be a way [nurses] could support their patients." TS 11:52 "In the case of patients with NSCLC, early testing is so important. So, advocating for that prompt biomarker testing to be done, making sure that it's comprehensive, that it's actually looking for all of those—I think it was 12 biomarkers—that I mentioned earlier. That this testing is done as soon as possible after diagnosis or progression. Something that I talk about all the time—personalized care, precision medicine—really matters. So, tailoring treatments for patients based on the biology of the tumor that's driving the cancer's growth is really crucial if you're going to be working as an oncology nurse. Another crucial thing, because it's changing so quickly, is to stay informed." TS 16:23

Dr. Yashbir Singh talks with Dr. Bonnie Joe about her journey from engineering to breast imaging and how a systematic, analytical approach shapes her clinical practice. Dr. Joe shares insights on breast screening guidelines, dense breast management, health equity, and how AI could help close gaps in access to care. Radiology: Imaging Cancer R&E Foundation

EPISODE DESCRIPTION:Libby Amber Shayo didn't just survive the pandemic—she branded it. Armed with a bun, a New York accent, and enough generational trauma to sell out a two-drink-minimum crowd, she turned her Jewish mom impressions into the viral sensation known as Sheryl Cohen. What started as one-off TikToks became a career in full technicolor: stand-up, sketch, podcasting, and Jewish community building.We covered everything. Jew camp lore. COVID courtship. Hannah Montana. Holocaust comedy. Dating app postmortems. And the raw, relentless grief that comes with being Jewish online in 2025. Libby's alter ego lets her say the quiet parts out loud, but the real Libby? She's got receipts, range, and a righteous sense of purpose.If you're burnt out on algorithm-friendly “influencers,” meet a creator who actually stands for something. She doesn't flinch. She doesn't filter. And she damn well earned her platform.This is the most Jewish episode I've ever recorded. And yes, there will be guilt.RELATED LINKSLibby's Website: https://libbyambershayo.comInstagram: https://www.instagram.com/libbyambershayoTikTok: https://www.tiktok.com/@libbyambershayoLinkedIn: https://www.linkedin.com/in/libby-walkerSchmuckboys Podcast: https://jewishjournal.com/podcasts/schmuckboysForbes Feature: Modern Mrs. Maisel Vibes https://www.forbes.com/sites/joshweissMedium Profile: https://medium.com/@libbyambershayoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform.For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Dr. Thomas Wisniewski, Director of NYU Langone's Alzheimer's Disease Research Center, shares insights from a recent study that projects new dementia cases in the US will double by 2060. New diagnostic tools have made it easier to identify early signs of Alzheimer's, and disease-modifying therapies are being approved, which can be effective if patients are treated in the earliest stages of the disease. AI is seen as a tool to help identify at-risk patients and routinely screen patients to manage the growing need for access to dementia care.  Thomas explains, "This was a study that was led by the NY Optimal Institute, which is directed by Dr. Joe Resh, who's really a leader in this area and many public health issues. He did a very thorough analysis along with his team that the annual number of incident dementia cases in the United States is projected to increase from current estimates of 500,000 to around 1 million in 2060. So basically doubling in white adults. Furthermore, in African Americans, this incidence of dementia rate is expected to triple, with the largest absolute increases in dementia cases going to be in the oldest old population." "There was perhaps a lack of awareness of the prevalence of dementia in past decades. But now the importance of making an accurate diagnosis and recognition of dementia is becoming much more prominent in the medical literature and in the medical profession. And that message, I think, is permeating to the lay public as well. So there hasn't been a change in the definition so much, but there is an increase in knowledge in the medical profession about the importance of making this diagnosis, and people living alone." "It's really been a dramatic change. So, apart from being a cognitive neurologist, I'm also a board-certified neuropathologist, and it used to be that making the definitive diagnosis of Alzheimer's disease required a chunk of brain. I'm delighted I don't need those chunks of brain anymore to make a diagnosis of Alzheimer's disease. There are now very clear clinical criteria and biomarker definitions for making a very accurate diagnosis of Alzheimer's disease." #NYULangoneAlzheimers #AlzheimersDisease #DiagnosingAlzheimers #AlzheimersResearch #MedAI med.nyu/centers-programs/alzheimers-disease-research/ Listen to the podcast here

Dr. Thomas Wisniewski, Director of NYU Langone's Alzheimer's Disease Research Center, shares insights from a recent study that projects new dementia cases in the US will double by 2060. New diagnostic tools have made it easier to identify early signs of Alzheimer's, and disease-modifying therapies are being approved, which can be effective if patients are treated in the earliest stages of the disease. AI is seen as a tool to help identify at-risk patients and routinely screen patients to manage the growing need for access to dementia care.  Thomas explains, "This was a study that was led by the NY Optimal Institute, which is directed by Dr. Joe Resh, who's really a leader in this area and many public health issues. He did a very thorough analysis along with his team that the annual number of incident dementia cases in the United States is projected to increase from current estimates of 500,000 to around 1 million in 2060. So basically doubling in white adults. Furthermore, in African Americans, this incidence of dementia rate is expected to triple, with the largest absolute increases in dementia cases going to be in the oldest old population." "There was perhaps a lack of awareness of the prevalence of dementia in past decades. But now the importance of making an accurate diagnosis and recognition of dementia is becoming much more prominent in the medical literature and in the medical profession. And that message, I think, is permeating to the lay public as well. So there hasn't been a change in the definition so much, but there is an increase in knowledge in the medical profession about the importance of making this diagnosis, and people living alone." "It's really been a dramatic change. So, apart from being a cognitive neurologist, I'm also a board-certified neuropathologist, and it used to be that making the definitive diagnosis of Alzheimer's disease required a chunk of brain. I'm delighted I don't need those chunks of brain anymore to make a diagnosis of Alzheimer's disease. There are now very clear clinical criteria and biomarker definitions for making a very accurate diagnosis of Alzheimer's disease." #NYULangoneAlzheimers #AlzheimersDisease #DiagnosingAlzheimers #AlzheimersResearch #MedAI med.nyu/centers-programs/alzheimers-disease-research/ Download the transcript here

Send us a textSeason 3 Episode 11Professor Chris Booth MBBS, FRCS – Consultant UrologistIn today's episode, we're joined by Professor Chris Booth, MBBS, FRCS — a leading Consultant Urologist and one of the UK's most respected voices in men's health. Professor Booth is the founder of CHAPS, a dedicated men's health charity established to improve awareness, early diagnosis, and access to better health services for men across the country.With a distinguished career in urology, Professor Booth has become a national expert in urological service redesign, championing modern, integrated care pathways that deliver faster, more effective, and more affordable treatment. His work is especially transformative in rural communities, where access to specialist services can be limited, and where his innovative approach has helped bridge the gap between primary and specialist care.Driven by a passion for prevention, early detection, and patient-focused care, Professor Booth continues to lead the conversation about how we can improve men's health outcomes and reduce avoidable deaths from diseases such as prostate cancer.We're thrilled to have him with us today to share his insights, experience, and vision for the future of men's health.https://chaps-uk.org#HeartTransplant#eatingdisorder#RareCondition#HealthJourney#LifeChangingDiagnosis#MentalHealth#Vulnerability#SelfCompassion#PostTraumaticGrowth#MedicalMiracle#BBCSports#Inspiration#Cardiology#Surgery#Podcast#Healthcare#HeartHealth#MedicalBreakthrough#EmotionalJourney#SupportSystem#HealthcareHeroes#PatientStories#CardiologyCare#MedicalJourney#LifeLessons#MentalWellness#HealthAwareness#InspirationalTalk#LivingWithIllness#RareDiseaseAwareness#SharingIsCaring#MedicalSupport#BBCReporter#HeartDisease#PodcastInterview#HealthTalk#Empowerment#Wellbeing#HealthPodcast#Harryhill#Aid's#MynaraCheck out our website at www.whostomanddick.comCheck out our website at www.whostomanddick.comCheck out our website at www.whostomanddick.com

When the system kills a $2.4 million study on Black maternal health with one Friday afternoon email, the message is loud and clear: stop asking questions that make power uncomfortable. Dr. Jaime Slaughter-Acey, an epidemiologist at UNC, built a groundbreaking project called LIFE-2 to uncover how racism and stress shape the biology of pregnancy. It was science rooted in community, humanity, and truth. Then NIH pulled the plug, calling her work “DEI.” Jaime didn't quit. She fought back, turning her grief into art and her outrage into action. This episode is about the cost of integrity, the politics of science, and what happens when researchers refuse to stay silent.RELATED LINKS• The Guardian article• NIH Grant• Jaime's LinkedIn Post• Jaime's Website• Faculty PageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Howie and Harlan are joined by cardiologist Ali Rahimi, the founder of ALYKA Health, which uses a personalized mobile app to help patients manage their heart health between doctor's visits. Harlan discusses new developments in GLP-1 obesity drugs, including untested microdose treatments; Howie reviews a landmark study investigating whether broad prostate cancer screening saves lives. Show notes: GLP-1 Drugs "Microdosing aims to extend the lifespan of the GLP-1 compounding market" NIH: Regulatory Framework for Compounded Preparations Health & Veritas Episode 140: Lee Schwamm: Smarter Healthcare Systems With AI "FDA takes on GLP-1 compounding boom with warnings about misleading marketing" "Should You Microdose GLP-1 Drugs?" "How microdosing GLP-1 drugs became a longevity 'craze'" "Bidding war between Pfizer, Novo Nordisk for obesity startup Metsera escalates" "Trump Negotiating Deal With Ozempic Maker to Sell Some Weight-Loss Drugs for $149""Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment" "How Ozempic's Maker Lost Its Shine After Creating a Wonder Drug" Ali Rahimi ALYKA Health Harlan Krumholz and Ali Rahimi, "Financial Barriers to Health Care and Outcomes After Acute Myocardial Infarction" "Why High Blood Pressure Matters to Your Health" Building a Better Delivery System: A New Engineering/Health Care Partnership NIH: The 21st Century Cures Act New Evidence on Prostate Cancer Screening and Breast Cancer Treatment National Cancer Institute: Cancer Stat Facts: Prostate Cancer" U.S. Preventive Services Task Force: Prostate Cancer: Screening" "The pros and cons of PSA tests for prostate cancer for midlife and older men" "Share on European Study of Prostate Cancer Screening — 23-Year Follow-up" "Early Detection of Prostate Cancer — Time to Fish or Cut Bait" "Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer" "Omission of Chest-Wall Irradiation after Mastectomy for Breast Cancer" In the Yale School of Management's MBA for Executives program, you'll get a full MBA education in 22 months while applying new skills to your organization in real time. Yale's Executive Master of Public Health offers a rigorous public health education for working professionals, with the flexibility of evening online classes alongside three on-campus trainings. Email Howie and Harlan comments or questions.  

Howie and Harlan are joined by cardiologist Ali Rahimi, the founder of ALYKA Health, which uses a personalized mobile app to help patients manage their heart health between doctor's visits. Harlan discusses new developments in GLP-1 obesity drugs, including untested microdose treatments; Howie reviews a landmark study investigating whether broad prostate cancer screening saves lives. Show notes: GLP-1 Drugs "Microdosing aims to extend the lifespan of the GLP-1 compounding market" NIH: Regulatory Framework for Compounded Preparations Health & Veritas Episode 140: Lee Schwamm: Smarter Healthcare Systems With AI "FDA takes on GLP-1 compounding boom with warnings about misleading marketing" "Should You Microdose GLP-1 Drugs?" "How microdosing GLP-1 drugs became a longevity 'craze'" "Bidding war between Pfizer, Novo Nordisk for obesity startup Metsera escalates" "Trump Negotiating Deal With Ozempic Maker to Sell Some Weight-Loss Drugs for $149""Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment" "How Ozempic's Maker Lost Its Shine After Creating a Wonder Drug" Ali Rahimi ALYKA Health Harlan Krumholz and Ali Rahimi, "Financial Barriers to Health Care and Outcomes After Acute Myocardial Infarction" "Why High Blood Pressure Matters to Your Health" Building a Better Delivery System: A New Engineering/Health Care Partnership NIH: The 21st Century Cures Act New Evidence on Prostate Cancer Screening and Breast Cancer Treatment National Cancer Institute: Cancer Stat Facts: Prostate Cancer" U.S. Preventive Services Task Force: Prostate Cancer: Screening" "The pros and cons of PSA tests for prostate cancer for midlife and older men" "Share on European Study of Prostate Cancer Screening — 23-Year Follow-up" "Early Detection of Prostate Cancer — Time to Fish or Cut Bait" "Ten-Year Survival after Postmastectomy Chest-Wall Irradiation in Breast Cancer" "Omission of Chest-Wall Irradiation after Mastectomy for Breast Cancer" In the Yale School of Management's MBA for Executives program, you'll get a full MBA education in 22 months while applying new skills to your organization in real time. Yale's Executive Master of Public Health offers a rigorous public health education for working professionals, with the flexibility of evening online classes alongside three on-campus trainings. Email Howie and Harlan comments or questions.  

When it comes to serious illness, early detection can be the difference between a difficult battle and a manageable path forward. But what if advanced diagnostics didn't require a referral, radiation, or even a reason to feel sick? In this episode of Med Tech Gurus, we sit down with Mike Wernli, Chief Operating Officer at Craft Health, to explore how they're flipping the script on traditional healthcare. With AI-enhanced full-body MRI scans, Craft Health is delivering hospital-grade insights in under 30 minutes—without contrast or complexity. But the technology is only part of the story. Mike opens up about the mindset shift required to empower patients to take control of their health before symptoms appear. He shares how Craft is combining clinical excellence with retail-like access, building a culture that thrives on purpose, and engaging communities in ways that truly matter. Whether you're an innovator in preventive care, a startup leader navigating consumer health, or someone passionate about shifting care upstream—this conversation offers both inspiration and a playbook.

EPISODE DESCRIPTIONAllison Applebaum was supposed to become a concert pianist. She chose ballet instead. Then 9/11 hit, and she ran straight into a psych ward—on purpose. What followed was one of the most quietly revolutionary acts in modern medicine: founding the country's first mental health clinic for caregivers. Because the system had decided that if you love someone dying, you don't get care. You get to wait in the hallway.She's a clinical psychologist. A former dancer. A daughter who sat next to her dad—legendary arranger of Stand By Me—through every ER visit, hallway wait, and impossible choice. Now she's training hospitals across the country to finally treat caregivers like patients. With names. With needs. With billing codes.We talked about music, grief, psycho-oncology, the real cost of invisible labor, and why no one gives a shit about the person driving you to chemo. This one's for the ones in the waiting room.RELATED LINKSAllisonApplebaum.comStand By Me – The BookLinkedInInstagramThe Elbaum Family Center for Caregiving at Mount SinaiFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Closing the Gap: Understanding Gender Disparities in Bladder Cancer Care, hosted by Martha K. Terris, MD, FACS, is a limited series spotlighting unique considerations for bladder cancer diagnosis and treatment among women. Dr Terris is department chair and a professor in the Department of Urology, the Witherington Distinguished Chair in Urology, and co-director of the Cancer Center at the Medical College of Georgia at Augusta University.  In part 1 of this 3-part series, Dr Terris discussed the prevalence of bladder cancer in women, as well as reasons for diagnostic disparities that contribute to poor treatment outcomes. She noted that this disease is often diagnosed at later stages in women than in men, often resulting in diagnoses of more advanced disease and translating to poorer outcomes. She added that although female patients represent a minority of those with urothelial carcinoma, retrospective data indicate that women tend to be diagnosed at later stages and consequently experience worse survival rates, regardless of the disease stage. Dr Terris identified several theories explaining why this diagnosis delay occurs. One possible reason is patient-related: women may be less likely than men to consult a physician when they notice blood in their urine because they may be conditioned to dismiss blood if they experience menstrual bleeding. However, physician behavior and bias also contribute to diagnostic disparities, Terris said. Women with suspected hematuria typically receive fewer imaging tests, she continued. Additionally, physicians may be biased, attributing hematuria to uterine bleeding, menstruation, or other benign causes.  Overall, Terris emphasized that early detection is key. If there is any suspicion of a malignancy, patients should be referred directly to a urologist, she stated. Urologists should be willing to work up cases that might ultimately be recurrent urinary tract infections or radiation cystitis to avoid undiagnosed cases of bladder cancer in women, she concluded.

Nov. 3, 2025 ~ Lloyd Jackson is joined by Dr. Rany Aburashed, CEO and founder of Neurogen Biomarking, to discuss how Alzheimer's develops silently and how to detect it early. All of that leads to their Alzheimer's Early Detection Testing event this Saturday in Dearborn! Visit MyBrainDay.com to register for the event today! Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

"[When] a lot of men think about prostate exams, they immediately think of the glove going on the hand of the physician, and they immediately clench. But really try to talk with them and discuss with them what some of the benefits are of understanding early detection. Even just having those conversations with their providers so that they understand what the risk and benefits are of having screening. And then educate patients on what a prostate-specific antigen (PSA) and digital rectal exam (DRE) actually are—how it happens, what it shows, and what the necessary benefits of those are," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer screening, early detection, and disparities. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by October 31, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to prostate screening, early detection, and disparities. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ Episode 149: Health Disparities and Barriers in Metastatic Castration-Sensitive Prostate Cancer ONS Voice articles: Gender-Affirming Hormones May Lower PSA and Delay Prostate Cancer Diagnosis in Transgender Women Healthy Lifestyles Reduce Prostate Cancer Mortality in Patients With Genetic Risk Hispanic Patients Are at Higher Risk for Aggressive Prostate Cancer but Less Likely to Get Treatment Leveling State-Level Tax Policies May Increase Equality in Cancer Screening and Mortality Rates Most Cancer Screening Guidelines Don't Disclose Potential Harms ONS book: Understanding Genomic and Hereditary Cancer Risk: A Handbook for Oncology Nurses ONS course: Genomic Foundations for Precision Oncology Clinical Journal of Oncology Nursing article: Barriers and Solutions to Cancer Screening in Gender Minority Populations Oncology Nursing Forum articles: Disparities in Cancer Screening in Sexual and Gender Minority Populations: A Secondary Analysis of Behavioral Risk Factor Surveillance System Data Symptom Experiences Among Individuals With Prostate Cancer and Their Partners: Influence of Sociodemographic and Cancer Characteristics Other ONS resources: Genomics and Precision Oncology Learning Library ONS Biomarker Database (refine by prostate cancer) American Cancer Society prostate cancer early detection, diagnosis, and staging page National Institutes of Health prostate cancer screening page U.S. Preventive Services Task Force prostate cancer screening recommendation statement To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "The recommendations are men [aged] 45 who are at high risk, including African American men and men who have a first-degree relative who has been diagnosed with prostate cancer younger than 65 should go through screening. And men aged 40 at an even higher risk, these are the men that have that one first-degree relative who has had prostate cancer before 65. Screening includes the PSA blood test and a digital exam. Those are the screening recommendations, although they are a little bit controversial." TS 3:42 "You still see PSAs and DREs as the first line because they're easier for primary care providers to perform. ... Those are typically covered by insurance, so they still play that role in screening. But with the advent of MRIs and biomarkers, these have really helped refine that screening process and determine treatment options for our patients. Again, those patients who may be at a bit of a higher risk could go for an MRI or have biomarkers completed. Or if they're on that verge with their Gleason score, instead of doing a biopsy, they may send the patient for an MRI or do biomarkers for that patient. ... These updated technologies put [patients] a little bit more at ease that someone's watching what's going on, and they don't have to have anything invasive done to see where they're at with their staging." TS 4:35 "Disparities in screening access exist based on race, socioeconomic status, gender identity, education, and geography. It's really hard in rural areas to get primary care providers or urologists who can actually see these patients, [and] sometimes in urban areas. So socioeconomic status can affect that, but also where a person lives. African American men with lower incomes and people in rural areas face the greatest barriers to receiving screening. It's also important to encourage anyone with a prostate to be screened and offer gender-neutral settings for patients to feel comfortable." TS 7:50 "I think a lot of men feel like if they have no symptoms, they don't have prostate cancer ... so a lot of patients may put off screening because they feel fine, [they] haven't had any urinary symptoms, it doesn't run in their family. ...With prostate cancer, there usually are not symptoms that a patient's having—they may have some urinary issues or some pain—but it's not very frequent that they have that. So, just making sure our patients understand that even though they're not feeling something, it doesn't mean there's not something else going on there." TS 12:53 "Prostate cancer found at an early age can be very curable, so it's really important for men to have those conversations with their providers about the risk and benefits of screening. And anyone that we can help along the way to be able to have those conversations, I think is a great thing for oncology nurses to do." TS 15:44

In this episode, Ziad Hanhan, MD, hosted a discussion about lung cancer diagnosis, surgical management, and evolving treatment paradigms. Dr Hanhan is a thoracic surgeon at Hackensack Meridian Health, chairman of Surgery at Bayshore Medical Center in Holmdel, New Jersey, and chief of Thoracic Surgery at Riverview Medical Center in Red Bank, New Jersey. He was joined by: Thomas Bauer, MD, the chair of surgery at Jersey Shore University Medical Center in Neptune Township, New Jersey, and Hackensack Meridian Health School of Medicine Rachel NeMoyer, MD, a thoracic surgeon at Hackensack Meridian Health Drs Hanhan, Bauer, and NeMoyer discussed current standards and future directions in thoracic oncology, emphasizing multidisciplinary collaboration and technological innovation. The conversation opened with an overview of lung cancer epidemiology, and the experts noted that this disease remains the leading cause of cancer-related mortality in both men and women. They explained that approximately 90% of lung cancer cases are attributable to tobacco use, making cessation a key preventive measure. They also emphasized that early detection through low-dose CT screening improves outcomes when the disease is identified at an early stage. However, despite these advances, they stated that most lung cancer cases in the United States continue to be diagnosed at stage III or IV, underscoring the need for improved screening adherence. They expanded on current lung cancer screening guidelines and noted that lung cancer often presents with nonspecific symptoms, such as chronic cough or hemoptysis, and that many cases are discovered incidentally on imaging. The surgeons also discussed diagnostic strategies for pulmonary nodules and emphasized a patient-tailored approach that balances diagnostic yield with procedural risk. They also acknowledged that emerging modalities, such as liquid biopsy and breath-based DNA detection, are promising but still investigational. They underscored that frailty assessment remains integral to surgical candidacy determination, with both clinical evaluation and pulmonary function testing guiding decision-making. The team also highlighted the role of multidisciplinary tumor boards in integrating surgical, medical, and radiation oncology perspectives. For early-stage disease, surgery remains the standard, whereas patients with stage III disease typically receive neoadjuvant therapy incorporating immuno-oncology agents. The group also discussed expanding surgical indications in select stage IV cases, reflecting improved survival associated with immunotherapy.

EPISODE DESCRIPTIONRebecca V. Nellis never meant to run a nonprofit. She just never left. Twenty years later, she's still helming Cancer and Careers after a Craigslist maternity-leave temp job turned into a lifelong mission.In this 60-minute doubleheader, we cover everything from theater nerdom and improv rules for surviving bureaucracy, to hanging up on Jon Bon Jovi, to navigating cancer while working—or working while surviving cancer. Same thing.Rebecca's path is part Second City, part Prague hostel, part Upper East Side grant writer, and somehow all of that makes perfect sense. She breaks down how theater kids become nonprofit lifers, how “sample sale feminism” helped shape a cancer rights org, and how you know when the work is finally worth staying for.Also: Cleavon Little. Tap Dance Kid. 42 countries. And one extremely awkward moment involving a room full of women's handbags and one very confused Matthew.If you've ever had to hide your diagnosis to keep a job—or wanted to burn the whole HR system down—this one's for you.RELATED LINKSCancer and CareersRebecca Nellis on LinkedIn2024 Cancer and Careers Research ReportWorking with Cancer Pledge (Publicis)CEW FoundationI'm Not Rappaport – Broadway InfoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship opportunities, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Guest: Jennifer Kistler, Breast Cancer Survivor & Healthcare ProfessionalHost: Jamie PrestonTopic: The importance of early detection and the emotional resilience of surviving breast cancerDiscussion Highlights:Life before diagnosis and how unexpected the news wasThe moment she heard the words, “You have breast cancer”Building a strong core of support during treatmentFinding friendship and purpose through shared experienceThe symbolism of ringing the bell and what it truly meansHow her perspective on health and strength has evolvedWhy every woman — even those without symptoms or family history — must prioritize screening www.YourHealth.Org

Is 2025 a pivotal inflection point for AI in health care? Dr. Connie Lehman, Co-Founder of Clairity, thinks so, and she has strong cause for optimism. Her organization's software-as-a-medical-device product, Clairity Breast, recently received authorization from the Food and Drug Administration as the first AI platform that predicts a woman's five-year risk of developing breast cancer.On this episode, Dr. Lehman shares her journey with Clairity, from the paper she read as a medical student that sparked the idea, to her experience navigating the new domain of image-based risk assessment with the FDA. Her current focus is on implementing the technology through education and advocacy.Dr. Lehman is passionate about advancing medicine toward risk assessment and disease prevention. Understanding risk empowers patients and their health care providers to choose the best path. Dr. Lehman envisions a future where image-based risk information is accessible and available to improve health outcomes for all.

In this special live episode of the SHE MD Podcast, Olivia Munn joins Dr. Thaïs Aliabadi, Mary Alice Haney, Dr. Shari Goldfarb, and Kristen Dahlgren, for a powerful Breast Cancer Awareness Month panel in New York City. The event coincided with NBC's Today Show coverage and the lighting of the Empire State Building in pink — marking the launch of a national conversation around early detection, AI, and prevention.Together, they explore how lifetime risk assessments, dense breast screening, and AI mammogram prediction tools like Clarity Breast are transforming breast health. The panel also discusses cancer vaccine research, genetic testing, and the importance of women knowing their individual risk scores.Listeners will hear Olivia's personal story of early detection after a high-risk score prompted further imaging, leading to her diagnosis and recovery. This episode offers clarity, action, and hope — empowering every listener to become their own health advocate and partner with their medical team.Subscribe to SHE MD Podcast for expert tips on PCOS, Endometriosis, fertility, and hormonal balance. Share with friends and visit the SHE MD website and Ovii for research-backed resources, holistic health strategies, and expert guidance on women's health and well-being.What You'll LearnHow lifetime risk assessment tools can identify breast cancer risk before symptoms appearWhy dense breast tissue requires supplemental screening beyond mammogramsHow AI predictive tools like Clarity Breast are revolutionizing early detectionThe promise of vaccine research and genetic testing in future breast cancer preventionKey Timestamps(00:00) Live event intro and Breast Cancer Awareness Month context(03:30) Olivia's story: risk score, MRI findings, and early diagnosis(13:00) Dr. Aliabadi and Dr. Goldfarb on dense breast screening and AI tools(16:00) Cancer vaccine and immunotherapy discussion with Kristen Dahlgren(27:00) Genetic testing and family history: understanding your risk(34:00) Audience Q&A: emotional recovery and advocacy(42:00) Is there support for young women being diagnosed with breast cancer?(51:30) Clarifying the term Risk AssessmentKey TakeawaysEvery woman should know her lifetime breast cancer risk scoreDense breasts may obscure cancers — MRI and ultrasound can save livesAI mammogram tools are changing detection from reactive to predictiveResearch into cancer vaccines offers hope for prevention and recurrence reductionAdvocacy and awareness remain key — early action leads to better outcomesGuest BiosOlivia MunnOlivia Munn is an actress, health advocate, and breast cancer survivor. After receiving a high lifetime risk assessment score, she underwent further imaging that revealed cancer across multiple quadrants, leading to a bilateral mastectomy. Since publicly sharing her diagnosis in 2024, she has dedicated her platform toward raising awareness about early detection, risk assessment, and empowering women with knowledge about their breast health.Dr. Shari Goldfarb, MDDr. Shari Goldfarb is a breast medical oncologist at Memorial Sloan Kettering, with a clinical focus on early and advanced breast cancer. Her research centers on survivorship, symptom management, fertility, sexual health, and quality of life for breast cancer patients. She participates in clinical trials aimed at improving outcomes for women during and after treatment.Kristen DahlgrenKristen Dahlgren is a former NBC correspondent who, after her own stage 2 breast cancer diagnosis, left journalism to found the Cancer Vaccine Coalition. She collaborates with top cancer centers to accelerate immunotherapy and vaccine development in breast cancer and advocates for preventive strategies beyond current standards.LinksOlivia Munn – https://www.instagram.com/oliviamunnDr. Shari Goldfarb – https://www.mskcc.org/profile/shari-goldfarbKristen Dahlgren – https://www.linkedin.com/in/kristen-dahlgren-886519292/Donna McKay – https://www.bcrf.org/teamResources MentionedBreast Cancer Research Foundation (BCRF) – Funding for innovative breast cancer research and prevention programs

In this episode of Longevity by Design, host Gil Blander sits down with Florence Comite, MD, physician-scientist and founder of the Comite Center for Precision Medicine & Healthy Longevity. They explore why a one-size-fits-all approach to longevity falls short and how personalized data, from biomarkers to genetics, can spot early signs of disease before symptoms appear.Florence explains her “Nof1” method, which uses deep testing, wearables, and personal history to craft precise health plans. She highlights how sleep, more than exercise or diet, shapes long-term health but remains hard for most people to optimize. Using real-world examples, Florence shows why tracking markers like insulin and hormones matter, and why most people need support to turn health knowledge into action.The conversation covers the limits of standard medical care, the value of knowing your family history, and how even the best routines must adapt over time. Florence urges listeners to get curious about their own data and take steps—however small—toward better health.Guest-at-a-Glance 

This life-saving conversation is for anyone who has—or loves someone who has—breasts. It's what to look for, what to ask, what screenings you *actually need* (not just what is offered), and every decision point you have (even if it's not offered to you) if you are facing surgery.   This Breast Cancer Awareness Month, Glennon, Abby, and Amanda empower us with the most vital tool we have: information. Amanda reflects on how self-advocacy led her to her own breast cancer diagnosis—and we hear from the pod squad about how Amanda's transparency helped save their lives. Then, we're joined by Amanda's renowned doctor, Dr. Lucy M. De La Cruz, who reminds us that every patient has agency—and shares how to choose the treatment path that's right for you. And special shout out and thanks to Pod Squader Lori Mihalich-Levin (@mindfulreturn) for being such a special part of this story! If you or someone you love has been diagnosed with breast cancer, please save this episode or send it to the people you love. We love you.  For more on Amanda's Breast Cancer journey:  - Amanda's Diagnosis and What's Next (Part 1) - Amanda's Diagnosis and What's Next (Part 2) - Amanda Returns Post Surgery: Here's What She Wants You to Know  - What Amanda's Learned About Life, Love & Community (Post Surgery Pt 2)  - Early Detection, Mammograms & Breast Cancer Care with Dr. Rachel Brem  - Expert Advice on Genetic Testing, Cancer Prevention & Care Disparities with Dr. Rachel Brem  About Dr. De La Cruz:  Dr. Lucy M. De La Cruz is an internationally recognized breast surgical oncologist and the youngest Latina Chief of Breast Surgery in an academic institution in the United States. She serves as Chief of Breast Surgery and Director of the Betty Lou Ourisman Breast Health Center at MedStar Georgetown University Hospital, a nationally ranked center of excellence in breast cancer care. Dr. De La Cruz specializes in nipple-sparing mastectomies with structural preservation and resensation, with a focus on highly specialized single-stage implant reconstruction. Patients describe her not only as a world-class surgeon, but as a fierce advocate and mentor—especially for women navigating the complexities of diagnosis, treatment, and survivorship. 

Sally Wolf is back in the studio and this time we left cancer at the door. She turned 50, brought a 1993 Newsday valedictorian article as a prop, and sat down with me for a half hour of pure Gen X therapy. We dug into VHS tracking, Red Dawn paranoia, Michael J. Fox, Bette Midler, and how growing up with no helmets and playgrounds built over concrete somehow didn't kill us.We laughed about being Jewish kids in the suburbs, the crushes we had on thirty-year-olds playing teenagers, and what it means to hit 50 with your humor intact. This episode is part nostalgia trip, part roast of our own generation, and part meditation on the privilege of being alive long enough to look back at it all. If you ever watched Different Strokes “very special episodes” or had a Family Ties lunchbox, this one's for you.RELATED LINKSSally Wolf Official WebsiteSally Wolf on LinkedInSally Wolf on InstagramCosmopolitan Essay: “What It's Like to Have the ‘Good' Cancer”Oprah Daily: “Five Things I Wish Everyone Understood About My Metastatic Breast Cancer Diagnosis”Allure Breast Cancer Photo ShootTom Wilson's “Stop Asking Me the Question” SongFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This episode is sponsored by IDEXX This podcast episode, hosted by Adam Christman, DVM, MBA, features oncologists Dana Connell, DVM, MPH, DACVIM (Oncology) and Zachary L. Neumann, DVM, MS, DACVIM (Oncology), discussing the significance of early cancer detection in dogs. The conversation focuses on the IDEXX Cancer Dx testing. The doctors explain how the test, which can be included in routine wellness exams, provides rapid results, enabling veterinarians to make timely diagnoses and improve treatment outcomes. They also touch on the importance of the veterinary team in communicating sensitive news to pet owners and the future potential of the test to screen for other types of cancer.

October means it's time to talk boob health!

In this episode, David Harding, Senior Vice President of Pipeline Product Management at Exact Sciences, discusses a new survey of healthcare executives on multi-cancer early detection. He shares insights on system readiness, patient demand, and the barriers health systems face in adopting this transformative approach to cancer screening.This episode is sponsored by Exact Sciences.

Dr. Nikki Maphis didn't just lose a grant. She lost a lifeline. An early-career Alzheimer's researcher driven by her grandmother's diagnosis, Nikki poured years into her work—only to watch it vanish when the NIH's MOSAIC program got axed overnight. Her application wasn't rejected. It was deleted. No feedback. No score. Just gone.In this episode, Oliver Bogler pulls back the curtain on what happens when politics and science collide and promising scientists get crushed in the crossfire. Nikki shares how she's fighting to stay in the field, teaching the next generation, and rewriting her grant for a world where even the word “diversity” can get you blacklisted. The conversation is raw, human, and maddening—a reminder that the real “war on science” doesn't happen in labs. It happens in inboxes.RELATED LINKS:• Dr. Nikki Maphis LinkedIn page• Dr. Nikki Maphis' page at the University of New Mexico• Vanguard News Group coverage• Nature article• PNAS: Contribution of NIH funding to new drug approvals 2010–2016FEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

David Harding, senior vice president, pipeline product management at Exact Sciences, joins HealthLeaders for a discussion on how to help health system leaders understand the foundation of Multi-Cancer Early Detection (MCED) and how it can impact cancer diagnosis, drive innovation and improve patient outcomes. Information presented is not clinical, diagnostic, or treatment advice for any particular patient. Providers should use their clinical judgement and experience when deciding how to diagnose or treat patients. Exact Sciences does not recommend or endorse any particular course of treatment or medical choice.

Carla Tardiff has spent 17 years as the CEO of Family Reach, a nonprofit that shouldn't have to exist but absolutely does—because in America, cancer comes with a price tag your insurance doesn't cover.We talk about shame, fear, burnout, Wegmans, Syracuse, celebrity telethons, and the godforsaken reality of choosing between food and treatment. Carla's a lifer in this fight, holding the line between humanity and bureaucracy, between data and decency. She's also sharp as hell, deeply funny, and more purpose-driven than half of Congress on a good day.This episode is about the work no one wants to do, the stuff no one wants to say, and why staying angry might be the only way to stay sane.Come for the laughs. Stay for the rage. And find out why Family Reach is the only adult in the room.RELATED LINKSFamily ReachFinancial Resource CenterCarla on LinkedInMorgridge Foundation ProfileAuthority Magazine InterviewSyracuse University FeatureFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Connect with us via text! Sit down with our managing editor to get the dish on this DERMASCOPE's October. Hear about the "Working Together to Fight Skin Cancer: Education, Prevention, & Early Detection" webinar on October 20, the October issue with a beautiful cover featuring Face Reality Skincare, and an exclusive giveaway on DERMASCOPE's Instagram! As always, check the links below to learn more about anything you heard in this episode! Follow DERMASCOPE:Instagram: @dermascopeFacebook: facebook.com/dermascopePinterest: @dermascopeTikTok: @dermascopeAdditional Links:Visit our website.Learn more about this podcast.Subscribe to the magazine.Read the October 2025 issue. Get an anniversary box.Register for the October 20 webinar.

In this episode of Confessions of a Male Gynecologist, Dr. Shawn Tassone explores the vital connection between hormone health and breast cancer screening. Drawing from his best-selling book The Hormone Balance Bible, he breaks down the most common screening methods — mammography, ultrasound, and thermography — and explains how each one works, their benefits, and their limitations. Dr. Tassone also discusses emerging imaging technologies, like the QT scan, and emphasizes why understanding your options is key to prevention and peace of mind. Whether you're curious about alternative testing methods or looking to make informed choices about your breast health, this episode empowers women with knowledge to take charge of their own care. Episode Highlights: Key takeaways from The Hormone Balance Bible on hormone imbalances and overall wellness The differences between mammography, ultrasound, and thermography in breast cancer screening Why thermography is a physiological test, while mammography and ultrasound focus on structure The pros and cons of each screening method — and why no single test is perfect How ultrasound can sometimes catch what mammograms miss The lower false-positive rate associated with thermography The promise of emerging imaging technologies like the QT scan Why prevention is more powerful than detection in the fight against cancer How to choose the breast screening method that aligns best with your health goals and comfort level Episode Resources: Dr. Shawn Tassone's Practice | Tassone Advanced Gynecology Dr. Shawn Tassone's Book | The Hormone Balance Bible Dr. Shawn Tassone's Integrative Hormonal Mapping System | Hormonal Archetype Quiz Medical Disclaimer This podcast and website represent the opinions of Dr. Shawn Tassone and his guests. The content here should not be taken as medical advice and is for informational purposes only. Because each person is so unique, please consult your health care professional for any medical questions.

DianeKazer.com/PATIENT DianeKazer.com/RESOURCES DianeKazer.com/EXPLANTSOLUTION DianeKazer.com/PEPTIDEPOWER DianeKazer.com/SHOP DianeKazer.com/VIP DianeKazer.com/PURCHASEPEPTIDES DianeKazer.com/PURCHASEPEPTIDESVIP For decades, we've trusted the message: Catch it early, save your life. But what if the very tools built for “early detection” — mammograms, MRIs and scans — are exposing us to radiation, inflammation, and fear that may actually fuel disease instead of prevent it? This week's episode dismantles the myth of modern cancer screening — and uncovers a deeper truth about what really drives healing and prevention.

Jennifer J. Brown is a scientist, a writer, and a mother who never got the luxury of separating those roles. Her memoir When the Baby Is Not OK: Hopes & Genes is a punch to the gut of polite society and a medical system that expects parents to smile through trauma. She wrote it because she had to. Because the people who gave her the diagnosis didn't give her the truth. Because a Harvard-educated geneticist with two daughters born with PKU still couldn't get a straight answer from the very system she trained in.We sat down in the studio to talk about the unbearable loneliness of rare disease parenting, the disconnect between medical knowledge and human connection, and what it means to weaponize science against silence. She talks about bias in the NICU, the failure of healthcare communication, and why “resilience” is a lazy word. Her daughters are grown now. One's a playwright. One's an artist. And Jennifer is still raising hell.This is a conversation about control, trauma, survival, and rewriting the script when the world hands you someone else's lines.Bring tissues. Then bring receipts.RELATED LINKS• When the Baby Is Not OK (Book)• Jennifer's Website• Jennifer on LinkedInFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, visit outofpatients.show.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Breast cancer awareness, early detection, mammograms, and modern treatment options—learn what women 40+ need to know now. In this Breast Cancer Awareness Month special, we talk breast cancer signs, risk factors, and how early detection saves lives. Dr. Elizabeth O'Leary—breast surgeon and head of Lady Slipper Breast Center—shares practical guidance on breast cancer screening, genetics, lifestyle, and survivorship. If you've delayed your mammogram, this conversation is your nudge. We cover what's changed in breast cancer care, what to ask your providers, and how to advocate for yourself with confidence.Timestamps(00:00) Introduction to Breast Cancer Awareness Month & why this episode matters(02:05) Meet Dr. Elizabeth O'Leary: training, Johns Hopkins, and founding Lady Slipper Breast Center(06:18) Patient-first care: time, personalization, and thriving after treatment(10:40) Lisa's breast cancer story: fear, surgery decisions, and believing for a cure(15:22) Early detection essentials: mammograms, dense breasts, and screening timelines(19:30) High-risk assessment at 25: who needs early imaging and why it matters(24:05) Genetics 101: family history, moving-target panels, and what results mean(28:48) Lifestyle factors: diet, exercise, stress, alcohol—what the research supports(34:12) Advocacy & self-trust: how to speak up and choose your care team(37:20) Hope & next steps: practical actions to take this week(39:15) Where to find Dr. O'Leary & Lady Slipper Breast CenterKey TakeawaysEarly detection saves lives. Annual mammograms (and MRI for select high-risk women) dramatically improve outcomes.High-risk assessment should start at 25. A formal risk review can identify women who need earlier or additional screening.Genetics is evolving. “Negative before” doesn't always mean negative now—panels and insights continue to expand.Lifestyle matters. Consistent movement, strength training, weight management, stress reduction, and limiting alcohol are linked to lower risk.You can be both calm and proactive. Ask questions, understand your options, and choose a team that treats the whole person.Guest BioDr. Elizabeth O'Leary, MD is a breast surgeon and founder of Lady Slipper Breast Center in Minnesota (St. Paul, St. Louis Park, Edina). Trained at the University of Minnesota and Johns Hopkins, she specializes in personalized, comprehensive breast care—from screening and diagnosis through treatment and survivorship—with a focus on early detection, minimally invasive approaches, and patient-centered outcomes.Resource LinksLady Slipper Breast Center (Dr. Elizabeth O'Leary): https://www.elizabetholearymd.comFind a high-risk breast clinic near you (search “breast cancer high risk clinic” + your city)Breast density info & screening options (ask your imaging center about tomosynthesis and MRI for high-risk patients)Lifestyle tools: activity trackers, strength programs for women 40+, and stress-reduction practices (breathwork, prayer, therapy)Tags/Keywordsbreast cancer awareness, breast cancer, early detection, mammogram,...

Confronting Cancer: Insights on Prevention, Early Detection & Treatment by Capital FM

Breast Cancer Awareness Month reminds us: early detection saves lives.

In honor of Breast Cancer Awareness Month, this episode of Docs in a Pod features Kimberly Channels, PA-C, from WellMed in New Tampa. Hosts Ron Aaron and Dr. Tamika Perry from WellMed at Redbird Square lead a powerful conversation about early detection, risk factors, and the importance of regular screenings. Docs in a Pod focuses on health issues affecting adults. Clinicians and other health partners discuss stories, topics and tips to help you live healthier. Docs in a Pod airs on Saturdays in the following cities:  7:00 to 7:30 am CT:  San Antonio (930 AM The Answer)  DFW (660 AM, 92.9 FM [Dallas], 95.5 FM [Arlington], 99.9 FM [Fort Worth])  6:30 to 7:00 pm CT:  Houston (1070 AM/103.3 FM The Answer)  7:00 to 7:30 pm CT:  Austin (KLBJ 590 AM/99.7 FM)  Docs in a Pod also airs on Sundays in the following cities:  1:00-1:30 pm ET:  Tampa (860 AM/93.7FM) 

Send us a textCan your dentist use artificial intelligence (AI) to spot health problems sooner? Imagine an extra set of eyes that never gets tired — that's what AI is bringing to dentistry. In this episode, Ahmed Sultan, BDS, PhD, director of the Division of Artificial Intelligence Research at the University of Maryland School of Dentistry, shares how new AI tools are helping dentists catch issues like cavities and oral cancer earlier. He also talks about why it matters to use diverse data, the ethical questions behind AI in health care, and how these advances could especially benefit people in rural and low-income communities.Tune in to discover how AI is shaping the future of dental visits — and maybe even protecting more than just your smile.Learn more about AI research at the University of Maryland School of Dentistry at https://www.dental.umaryland.edu/ai/Listen to The UMB Pulse on Apple, Spotify, Amazon Music, and wherever you like to listen. The UMB Pulse is also now on YouTube.Visit our website at umaryland.edu/pulse or email us at umbpulse@umaryland.edu.

This episode of Standard Deviation features Oliver Bogler in conversation with Dr Na Zhao, a cancer biologist caught in the crossfire of science, politics, and survival. Na's life reads like a brutal lab experiment in persistence.She grew up in China, lost her mother and aunt to breast cancer before she turned twelve, then came to the United States to chase science as both an immigrant and a survivor's daughter. She worked two decades to reach the brink of independence as a cancer researcher, only to watch offers and grants vanish in the political chaos of 2025.Oliver brings her story into sharp focus, tracing the impossible climb toward a tenure-track position and the human cost of a system that pulls the ladder up just as people like Na reach for it. This conversation pulls back the curtain on the NIH funding crisis, the toll on early-career scientists, and what happens when personal tragedy fuels professional ambition.Listeners will walk away with a raw sense of how fragile the future of cancer research really is, and why people like Na refuse to stop climbing.RELATED LINKSDr Zhao at Baylor College of MedicineDr Zhao on LinkedInDr Zhao's Science articleIndirect Costs explained by US CongressFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

How do you respond when a friend faces a diagnosis that changes everything? What does real support look like during breast cancer treatment? In this episode, you’ll hear how friendship, early detection, and self-advocacy made a difference. You’ll also learn about the challenges of treatment, the role of caregivers, and ways communities rally when it’s needed most. Discover what it takes to face fear and make critical decisions. Hear two friends describe finding strength and asking for help. See why early action and support networks can impact recovery. Key Questions Answered How did Anne-Laure discover her breast cancer? How old was Anne-Laure when she was diagnosed with breast cancer? What was Anne-Laure’s experience with her initial diagnosis? How did Anne-Laure finally receive an accurate diagnosis? What type of breast cancer was Anne-Laure diagnosed with? How soon after diagnosis did Anne-Laure begin treatment? Did Ann-Laure use cold caps to try to keep her hair during chemotherapy? What was the role of friends and support in Anne-Laure’s journey? How did Anne-Laure and her husband communicate about her diagnosis and treatment? How did Anne-Laure handle the emotional impact and fear during her breast cancer journey? How did Anne-Laure and Rochelle support each other as friends through the process? What advice does Anne-Laure offer about early detection and self-advocacy? How did the experience change Anne-Laure’s approach to accepting help? How did Anne-Laure process and talk to herself through her treatment? How did Anne-Laure and her community celebrate treatment milestones? Timestamped Overview 00:00 Self-Discovery of Unusual Growth 03:25 Considering a Second Opinion 09:06 "Princess Diana's Influence on Cold Caps" 11:23 Hair Perception and Dry Ice Delivery 15:52 Hospital Freezers: Aiding Neuropathy Treatment 17:00 Finding Humor in Cold Caps 22:59 "Embracing Limits and Early Detection" 24:01 Early Detection Saved My Life 29:25 "Caregiver Struggles and Attention" 32:07 Support Network Eases Transition 35:37 Proactive Help and Support 38:20 Overcoming Fear Through Understanding Support The Rose HERE. Subscribe to Let’s Talk About Your Breasts on Apple Podcasts, Spotify, iHeart, and wherever you get your podcasts.See omnystudio.com/listener for privacy information.

Dr. Monty Pal and Dr. Matteo Lambertini discuss a compelling global study on the clinical behavior of breast cancer in young BRCA1 and BRCA2 carriers, the association of pre-diagnostic awareness of BRCA status with prognosis, and the importance of identifying healthy people who are at risk of carrying the BRCA1/2 pathogenic variants. TRANSCRIPT Dr. Monty Pal: Well, hello everyone, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist, professor, and vice chair of medical oncology at the City of Hope Comprehensive Cancer Center in Los Angeles. Now, when we think about genetic testing, whether for patients diagnosed with breast cancer or for other family members of them, it seems to be widely underutilized. Today, we're going to be discussing a recently published study in the Journal of Clinical Oncology that reported on the clinical behavior of breast cancer and specifically young BRCA1 and BRCA2 carriers, and the association of pre-diagnostic awareness of BRCA status with prognosis. I thought this was just a fascinating piece, and I honestly couldn't wait to have this conversation. It's a really compelling paper that highlights the importance of identifying healthy people who are at risk of carrying the BRCA1/2 pathogenic variants, and really the need for genetic counseling and testing to inform people about early detection that could lead to a better prognosis. I'm really delighted to welcome the study's lead author, Dr. Matteo Lambertini. He really needs no introduction. He's very well known in the breast cancer world for his amazing contributions to fertility in the context of breast cancer, to pregnancy in the context of breast cancer, and genetic testing. He's an associate professor at the University of Genova, and a breast cancer medical oncologist at the San Martino Polyclinic Hospital in Genova, Italy.  Dr. Lambertini, thank you so much for joining us today. Dr. Matteo Lambertini: Thank you very much, Dr. Pal. It's a great pleasure. Dr. Monty Pal: Oh, thanks. And just FYI, if you're listening in and you want to hear our disclosures, they're all listed at the transcript of this podcast.  So, I poured through this paper [Clinical Behavior of Breast Cancer in Young BRCA Carriers and Prediagnostic Awareness of Germline BRCA Status] yesterday, Dr. Lambertini, and first of all, congratulations on this study. This was a huge international multicenter effort, 4,752 patients. How did you pool all these patients with young breast cancer? Dr. Matteo Lambertini: Thanks a lot for the question. Yes, this was an effort made by several centers all over the world. The main idea behind the creation of this network that we have named as BRCA BCY Collaboration, was to get as many data as possible in a sort of niche patient population in the breast cancer field, meaning women diagnosed with breast cancer at the age of 40 years or younger, and all of them being BRCA carriers. We know that around, in the Western world, around 5% of breast cancer cases are being diagnosed under the age of 40 years, and among them around 10-15% are BRCA carriers. So, I would say it's a relatively rare patient population where we did not have a lot of evidence to support our choices in terms of counseling on treatment, prevention, and oncofertility as well. That was the idea behind the creation of this network that includes many centers. Dr. Monty Pal: Yeah. You know, what's so interesting about this is that you sort of draw this line between patients who have BRCA testing at the time of diagnosis and then BRCA testing earlier in their course and then leading to a diagnosis perhaps. And I think that's where really sort of the dichotomy in outcome sits. Can you maybe elaborate on this and tell us about timing of genetic testing in this study and what that meant ultimately in terms of prognosis? Dr. Matteo Lambertini: In this specific analysis from this large network, including almost 5,000 women with breast cancer diagnosed at the age of 40 years or younger and being a BRCA carrier, we looked specifically into the timing of genetic testing because this is a retrospective study and the criteria for inclusion are those that I have just mentioned, so diagnosis at a young age plus carrying germline BRCA pathogenic or likely pathogenic variant. In this analysis, we have looked into the time the patient has got the genetic testing and particular we focused on two populations: those that were diagnosed, knowing already to be a BRCA carrier, and those that got tested after being diagnosed with breast cancer. And the main findings from this analysis have been that knowing to be a BRCA carrier was associated with a lower stage at the time of diagnosis, meaning more T1 tumors, so a tumor less than 2 cm, more node-negative disease, and this translated into less aggressive treatment, so less often axillary dissection, less often use of chemotherapy and anthracycline-based chemotherapy. And even more importantly, we have seen a better overall survival for those patients that were diagnosed already knowing to be BRCA carriers as compared to those tested after breast cancer diagnosis. These results after adjusting for all the confounding, stage, treatment and so on, there was not significant anymore, meaning that it's not the timing of test per se that is probably leading to a better survival, but it is the fact that knowing to be a BRCA carrier would likely translate into having access to all the preventive measures that we have in this setting and this will translate into an overall survival benefit, so in terms of saving more lives in young BRCA carriers. Dr. Monty Pal: I think it's such an important point, and it's one that I think might sound implicit, right, but it needs to be proven, I think, through a study like this. You know, the fact that finding this early, identifying the mutation, doing enhanced screening, and so forth, is really going to lead to superior clinical outcomes. One of the things that I think many people puzzle over, including myself, is what to do? I personally occasionally will see BRCA altered patients in the context of prostate cancer. But that's a very different population of individuals, right? Typically older men. In young females with BRCA mutation, I guess there's a specific set of considerations around reproductive health. You'd already highlighted preventive strategies, but what sorts of things should we be talking about in the clinics once a patient's diagnosed and once perhaps their breast cancer diagnosis is established? Dr. Matteo Lambertini: Yes, exactly. Knowing to be a BRCA carrier has a lot of implications from prevention to treatment to survivorship issues including reproductive counseling. And this is important not only for the patient that has been diagnosed with breast cancer but also for all the family members that will get tested and maybe identify with this sort of genetic alteration before diagnosis of cancer. Why this is important is because we have access to very effective preventive measures, a few examples: MRI screening, which starts at a very young age and normally young women don't have an effective screening strategy outside the BRCA field. Also, primary preventive measures, for example, risk-reducing surgery. These women are known to have a high risk of breast cancer and high risk of ovarian cancer. So the guidelines are suggesting to undergo risk-reducing salpingo-oophorectomy at a young age, so 35 to 40 years in BRCA1 carrier, 40 to 45 years in BRCA2 carrier. And also risk-reducing mastectomy should be discussed because it is a very effective way to prevent the occurrence of breast cancer. And in some situations, including the setting that we are talking about, so young women with breast cancer, BRCA carrier, also risk-reducing mastectomy has shown to improve overall survival.  On the other side, once diagnosed with breast cancer, nowadays knowing to be or not a BRCA carrier can make a difference in terms of treatment. We have PARP inhibitors in the early setting, in the adjuvant setting as well as in the metastatic setting. And in terms of survivorship implication, one of the critical aspects for young women is the oncofertility care which is even more complicated when we talk about BRCA carriers that are women candidates for gynecological surgery at a very young age. So this sort of counseling is even more complicated. Dr. Monty Pal: One of the other things, and this is subtle in your paper and I hope you don't mind me bringing it up, is the difference between BRCA1 and BRCA2. It really got me thinking about that because there are differences in phenotype and manifestation. Do you mind just expanding on that a little bit for the audience because I think that's a really important reminder that you brought up in the discussion? Dr. Matteo Lambertini: The difference between BRCA1 and BRCA2 carriers has been known that there are different phenotypes of breast cancer that are more often diagnosed in these two different populations. Normally BRCA1 carriers have a higher likelihood to develop a triple negative breast cancer as compared to BRCA2 carriers, more likely to develop a hormone receptor-positive HER2-negative disease. In this study, again, a specific population of young women with breast cancer, we have seen the same findings, mostly triple negative disease in BRCA1 carrier, mostly luminal-like disease in BRCA2 carrier. But what's novel or interesting from this study is to look also at the age at the time of diagnosis of this disease. And particularly in BRCA1 carriers, we should be sort of more careful about diagnosis of breast cancer and also other primary tumors including ovarian cancer because the risk of developing these malignancies is higher even at a younger age as compared to BRCA2 carriers. And this has implications also in the primary and secondary prevention that we were talking about earlier. Dr. Monty Pal: Oh, interesting. I guess the fundamental question then from your paper becomes, how do we get at the right patients for screening for BRCA1 and BRCA2? And I realize our audience here is largely oncologists who are going to be listening to this podcast, oncology providers, MDs, nurses, etc. But maybe speak for a moment to the general practitioner. Are there things that, for instance, a general practitioner should be looking for to say, “Wait a minute, this patient's high risk, we should consider BRCA1, BRCA2 testing or germline screening”? Dr. Matteo Lambertini: Yes, it's a very important question for the breast cancer community. After the updated ASCO guideline, the counseling is way easier because right now the age cutoff goes up to 65 years, meaning that all the patients diagnosed with breast cancer below the age of 65 years should be tested these days. And then above the age of 65, there are different criteria like triple-negative disease or family history. From a general practitioner standpoint, it's of course a bit more difficult, but knowing particularly the family history of the person that they have in front will be crucial to know if there are cases of breast cancer diagnosed at a young age, maybe triple-negative cases, knowing cases of ovarian cancer in first-degree relatives or pancreatic cancer in first-degree relatives, and of course cases of prostate cancer as well. So, I would say probably mostly the family side will be important from a general practitioner perspective.  From an oncology one, the other point that I think is important to stress also based on the data that we have shown in this publication is that having a case of breast cancer known to carry a BRCA pathogenic or likely pathogenic variant. It means that all the people around this case should get tested and if found to be BRCA carrier and healthy carrier, these people should also undergo the primary and secondary prevention strategies because this is very critical also to improve their outcomes and try to avoid the developing of breast or ovarian cancer, but also in the case of diagnosis of this disease, a diagnosis at an earlier stage, as we have seen in this paper. Dr. Monty Pal: Brilliant. I'm going to diverge from our list of questions here and close by asking a question that I have at the top of my mind. You're very young. I know our podcast listeners can't see you, but you're very, very young. Dr. Matteo Lambertini: Thank you. Thank you for that. Not so young but yeah. Dr. Monty Pal: You have nearly 300 papers. Your H-index is 67. You've already made these seminal contributions, as I outlined it from the outset, regarding fertility, regarding use of GnRH analogs, regarding pregnancy and breast cancer. What are you studying now? What are you really excited about right now that you're doing that you think might potentially be practice changing? Give us a little teaser. Dr. Matteo Lambertini: Yeah. Thanks a lot, Dr. Pal. Receiving this compliment from you is fantastic. So, thanks a lot for that. From my side, in terms of my research, I've been interested in the field of breast cancer in young women since the start of my training. I've had very good mentors from Italy, from Europe, from the U.S. I'm still interested in this field, so I think we still have a lot to learn to try to improve the care of young women with breast cancer. For example, the oncofertility care, which is something I worked a lot over the past years. Now with all the new treatment options, there's a sort of new chapter of oncofertility counseling. So, what's the impact of immunotherapy? What's the impact of the new targeted agents?  More on the genetic aspects, now we know that there's not only BRCA1 or BRCA2. There are a lot of other different genes that may increase the risk of breast cancer and other malignancies. And also for these genes, we really don't have a lot of evidence to counsel women on prognosis, treatment, prevention strategy. So we need to learn way more for this special patient population that are quite rare, and so we really need a multicenter academic effort to try to give some evidence in this field. Dr. Monty Pal: Yeah. It's tough because these are rare circumstances, but, you know, I think that you've done really well to sort of define some collective experiences that I think really define therapy. I mean, I just remember when I was in training 25 years ago, just reading through textbooks where all the experience around breast cancer and pregnancy was really just very sort of anecdotal almost, you know? And so it's great to see that the state of the science has moved forward.  Well, gosh, I really enjoyed our conversation today. I think your study really reminds us how powerful genetic information is in terms of improving outcomes. And, you know, hopefully this will lead some individuals to perhaps test more broadly in appropriate settings. So, thank you so much, Matteo, for joining us today with your fantastic insights on the ASCO Daily News Podcast. Dr. Matteo Lambertini: Thank you very much, Dr. Pal. It's a real pleasure. Dr. Monty Pal: And thanks to our listeners too. You'll find a link to Dr. Lambertini's study in the transcript of this episode. Finally, if you value the insights that you heard today on the ASCO Daily News Podcast, please rate, review, and subscribe wherever you get your podcasts. Thanks a ton. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:    Dr. Sumanta (Monty) Pal  @montypal  Dr. Matteo Lambertini @matteolambe   Follow ASCO on social media:     @ASCO on Twitter    ASCO on Bluesky   ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Monty Pal:   Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview  Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical  Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis  Dr. Matteo Lambertini: Consulting or Advisory Role: Roche, Novartis, Lilly, AstraZeneca, Pfizer, MSD, Exact Sciences, Gilead Sciences, Seagen, Menarini, Nordic Pharma Speakers' Bureau: Takeda, Roche, Lilly, Novartis, Pfizer, Sandoz, Ipsen, Knight Therapeutics, Libbs, Daiichi Sankyo, Gilead Sciences, AstraZeneca, Menarini, AstraZeneca, Menarini Research Funding (Inst.): Gilead Sciences Travel, Accommodations, Expenses: Gilead Sciences, Daiichi Sankyo Europe GmbH, Roche

Recently the Endocrine Society held its 12th annual Type 1 Diabetes Fellows Series program, which combines comprehensive education on type 1 diabetes with career development opportunities to build knowledge, practical skills, and a lasting network of colleagues. For this episode, host Aaron Lohr talks with Desmond Schatz, MD, medical director of the Diabetes Institute and director of the Clinical Research Center at the University of Florida. Dr. Schatz gave a talk at the fellows series program titled, “Immunotherapies for Type 1 Diabetes: Need for Early Detection and Screening.” This year’s fellows series program and this episode were made possible by the support of Abbott Diabetes Care, CeQur Corp., Dexcom Inc., Insulet Corp., Breakthrough T1D (formerly the Juvenile Diabetes Research Foundation), Lilly USA, Mankind Pharma Limited, Medtronic Inc., Novo Nordisk Inc., and Vertex Pharmaceuticals Inc. Show notes are available at https://www.endocrine.org/podcast/enp103 — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

Katie Henry has seen some things. From nonprofit bootstraps to Big Pharma boardrooms, she's been inside the machine—and still believes we can fix it. We go deep on her winding road from folding sweaters at J.Crew to launching a vibrator-based advocacy campaign that accidentally changed the sexual health narrative in breast cancer.Katie doesn't pull punches. She's a born problem solver with zero tolerance for pink fluff and performative empathy. We talk survivor semantics, band camp trauma, nonprofit burnout, and why “Didi” is the grandparent alter ego you never saw coming.She's Murphy Brown with a marimba. Veronica Sawyer in pharma. Carla Tortelli with an oncology Rolodex. And she still calls herself a learner.This is one of the most honest, hilarious, and refreshingly real conversations I've had. Period.RELATED LINKS:Katie Henry on LinkedInKatie Henry on ResearchGateLiving Beyond Breast CancerNational Breast Cancer CoalitionFEEDBACK:Like this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship inquiries, email podcast@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.